SCHEMBL19975486

SCHEMBL19975486

COc1ccccc1NC(C)C(O)C(=O)NC(C)(C)c1cccc(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
GAA P10253 1/20 0.44
PKM P14618 1/20 0.44
KMT2A Q03164 6/20 0.41
MEN1 O00255 5/20 0.41
MAPT P10636 2/20 0.41
GRIK1 P39086 1/20 0.41
LPAR1 Q92633 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
NPSR1 Q6W5P4 2/20 0.39
ALOX12 P18054 1/20 0.39
ALDH1A1 P00352 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21176364 0.82 LPAR1 (0.48) LMNAGAAPKMKMT2AMEN1
SCHEMBL19975165 0.81 USP36 (0.43) LMNAGAAMAPTCYP2C19ALDH1A1
SCHEMBL19974969 0.79 MAPT (0.51) LMNAGAAPKMKMT2AMEN1
SCHEMBL19975312 0.77 LMNA (0.35) LMNAGAAPKMKMT2AMEN1
SCHEMBL19974736 0.74 HTT (0.43) LMNAGAAKMT2AMEN1ALDH1A1
SCHEMBL19974851 0.74 POLB (0.58) LMNAPKMKMT2AMEN1MAPT
SCHEMBL19974850 0.74 POLB (0.58) LMNAPKMKMT2AMEN1MAPT
SCHEMBL19975414 0.74 ALDH1A1 (0.49) LMNAGAAPKMKMT2AMEN1
SCHEMBL21176316 0.73 MEN1 (0.39) LMNAGAAPKMKMT2AMEN1
SCHEMBL19974855 0.70 ALDH1A1 (0.50) LMNAGAAPKMKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C LMNA 1909/4885GAA 75/4885PKM 2897/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C LMNA 2058/4885GAA 107/4885PKM 3299/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C LMNA 1909/4885GAA 75/4885PKM 2897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.